Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) — Financial Flexibility Index
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a Financial Flexibility Index of 0.23x as of September 2025. Free cash flow of CN¥47.42 Million (operating CF CN¥43.77 Million minus capex CN¥3.65 Million) represents 0% of total liabilities (CN¥207.05 Million). Also explore how fast is Shanghai Fudan-Zhangjiang Bio-Pharmaceut growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Financial Flexibility Index (2006–2025)
Historical Financial Flexibility Index trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd across 20 annual periods. Check financial resilience of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2006–2025)
Year-by-year free cash flow to debt coverage for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) total market value.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.63x | CN¥173.76 Million | CN¥141.40 Million | CN¥273.93 Million | ▲ +539.4% |
| 2024 | 0.10x | CN¥27.90 Million | CN¥-14.77 Million | CN¥281.23 Million | ▼ -69.8% |
| 2023 | 0.33x | CN¥169.98 Million | CN¥71.02 Million | CN¥518.12 Million | ▼ -6.1% |
| 2022 | 0.35x | CN¥252.57 Million | CN¥165.27 Million | CN¥722.99 Million | ▼ -46.9% |
| 2021 | 0.66x | CN¥389.02 Million | CN¥268.90 Million | CN¥591.58 Million | ▲ +108.3% |
| 2020 | 0.32x | CN¥155.41 Million | CN¥113.00 Million | CN¥492.21 Million | ▼ -35.6% |
| 2019 | 0.49x | CN¥309.62 Million | CN¥269.23 Million | CN¥631.68 Million | ▲ +7.9% |
| 2018 | 0.45x | CN¥211.73 Million | CN¥173.94 Million | CN¥466.08 Million | ▲ +10.7% |
| 2017 | 0.41x | CN¥103.65 Million | CN¥42.71 Million | CN¥252.65 Million | ▼ -45.8% |
| 2016 | 0.76x | CN¥187.40 Million | CN¥140.57 Million | CN¥247.70 Million | ▲ +41.5% |
| 2015 | 0.53x | CN¥136.04 Million | CN¥96.30 Million | CN¥254.43 Million | ▼ -40.6% |
| 2014 | 0.90x | CN¥133.26 Million | CN¥88.36 Million | CN¥148.06 Million | ▲ +12.4% |
| 2013 | 0.80x | CN¥146.82 Million | CN¥89.44 Million | CN¥183.29 Million | ▼ -1.3% |
| 2012 | 0.81x | CN¥224.88 Million | CN¥110.19 Million | CN¥277.18 Million | ▲ +55.1% |
| 2011 | 0.52x | CN¥82.58 Million | CN¥49.59 Million | CN¥157.81 Million | ▲ +2984.2% |
| 2010 | 0.02x | CN¥2.30 Million | CN¥-7.11 Million | CN¥135.45 Million | ▼ -96.5% |
| 2009 | 0.49x | CN¥63.54 Million | CN¥7.72 Million | CN¥130.46 Million | ▲ +410.0% |
| 2008 | -0.16x | CN¥-12.97 Million | CN¥-15.89 Million | CN¥82.57 Million | ▲ +14.5% |
| 2007 | -0.18x | CN¥-10.91 Million | CN¥-17.18 Million | CN¥59.34 Million | ▼ -75.7% |
| 2006 | -0.10x | CN¥-4.53 Million | CN¥-21.40 Million | CN¥43.32 Million | — |